No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, Latin America, Europe, and other international regions. The company's diverse offerings comprise both branded and generic drug formulations, with a strategic emphasis on therapeutic areas such as dermatology, respiratory conditions, and oncology. Additionally, Glenmark manufactures and supplies a variety of active pharmaceutical ingredients. The company's robust product pipeline includes several investigational therapies. Among its clinical-stage assets are ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody currently in Phase 2b trials for atopic dermatitis; ISB 1302, a HER2 x CD3 bispecific antibody undergoing Phase 1/2 studies for metastatic HER2-positive breast cancer; and ISB 1342, a CD38 x CD3 bispecific antibody in Phase 1 development for relapsed/refractory multiple myeloma. In its preclinical pipeline, Glenmark is advancing ISB 880 for anti-inflammatory applications; the T-cell engagers ISB 1908 and ISB 1909 for oncology indications; ISB 1442, an innate immune engager also targeting oncology; and GRC 39815, a retinoid-related orphan receptor gamma inhibitor aimed at treating chronic obstructive pulmonary disorder (COPD). Among its commercially available products is Ryaltris nasal spray, prescribed for allergic rhinitis. Founded in 1977, Glenmark Pharmaceuticals Limited is headquartered in Mumbai, India.
www.glenmarkpharma.comNo one on the platform currently holds GLENMARK.NS.
No tracked institution reports a position in GLENMARK.NS as of their last filing.
No one on the platform has traded GLENMARK.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 27.6% | -19.3% | -1.3% | — | — | — |
| Rev. Growth % | 27.1% | 9.2% | ||||
| Profit Margin % | 8.0% | 2.8% | 5.9% | |||
| Free Cash Flow Margin % | 11.4% | -1.4% | 0.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $167.9B | -1.7% | $82.23 | $64.25–$90.05 | — | 10 |
| 2028 | $187.1B | +11.4% | $99.94 | $89.74–$108.87 | — | 9 |
| 2029 | $208.1B | +11.2% | $110.25 | $98.93–$121.60 | — | 4 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 0 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-31 | $17.30 | $17.11 | -1.1% |
| 2026-05-29 | $18.30 | $10.88 | -40.5% |
| 2026-02-12 | $18.70 | $14.28 | -23.6% |
| 2025-08-13 | $12.90 | $1.66 | -87.1% |
| 2025-05-23 | $12.06 | $8.75 | -27.4% |
| 2025-02-13 | $14.05 | $12.30 | -12.5% |
| 2024-11-14 | $14.70 | $12.55 | -14.6% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| GLENMARK.NSGlenmark Pharmaceuticals Limited | $2371.70 | -1.96% | $669.3B | — |
| ALKEM.BOAlkem Laboratories Limited | $5155.00 | +1.29% | $615.4B | — |
| ALKEM.NSAlkem Laboratories Limited | $5161.00 | +1.44% | $617.1B | — |
| AUROPHARMA.BOAurobindo Pharma Limited | $1664.90 | -0.63% | $957.6B | — |
| AUROPHARMA.NSAurobindo Pharma Limited |
| $1660.00 |
| -1.18% |
| $955.1B |
| — |
| BIOCON.BOBiocon Limited | $381.00 | -2.55% | $519.5B | — |
| BIOCON.NSBiocon Limited | $382.00 | -2.21% | $521.9B | — |
Source: Financial Modeling Prep · peers by sector/industry